Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 30, 2015

Study Completion Date

January 30, 2019

Conditions
Breast Cancer
Interventions
DRUG

Bevacizumab

DRUG

Cyclophosphamide

DRUG

Methotrexate

BEHAVIORAL

Lifestyle: Diet

BEHAVIORAL

Lifestyle: Diet+Exercise

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

46202

Indiana Unversity Simon Cancer Center, Indianapolis

02130

Faulkner Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

01757

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Translational Breast Cancer Research Consortium

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER